Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announced that members of management will participate in two upcoming virtual investor conferences.
OSLO, Norway--(BUSINESS WIRE)-- Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming virtual investor conferences:
- B. Riley Radiation-Oncology Investor Day. Fireside chat on Tuesday, February 22, 2022 at 10:30 a.m. ET.
- 2022 Credit Suisse London Healthcare Conference. Company management will participate in 1x1 meetings on Wednesday, March 2, 2022.
About Oncoinvent
Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across solid cancers. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing a pipeline of novel products that use alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate cancer cells. Oncoinvent’s lead candidate, Radspherin®, is designed for treatment of metastatic cancers in body cavities, and its versality allows it to be deployed for the treatment of a variety of cancer indications. Radspherin® is in two ongoing Phase 1 studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005155/en/
For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: alfheim@oncoinvent.com
IR enquiries:
Courtney Turiano, Stern Investor Relations
Email: Courtney.Turiano@sternir.com
Source: Oncoinvent AS
View this news release online at:
http://www.businesswire.com/news/home/20220215005155/en
